Bedrijfsoverzicht
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on identifying and developing novel molecular candidates specifically designed to treat immuno-inflammatory diseases within the United States market. This company operates within the broader Healthcare sector, with its specific operational classification falling under the Biotechnology industry, distinguishing it as an entity dedicated to early-stage drug development rather than established product sales. The organization currently employs 69 individuals to support its research and development activities while maintaining a total market capitalization of $489.19 million. Despite possessing a substantial market cap relative to its operational output, the company reports annual revenue of only $7.83 million, indicating that its valuation is primarily driven by the potential of its future pipeline rather than current cash flows. The disparity between the $489.19 million market value and the $7.83 million in revenue suggests that the market is pricing in significant future growth expectations from its product candidates, such as Bosakitug, which is an anti-thymic stromal lymphopoietin molecule targeting specific immune pathways.
Financiële gezondheid
The company reported revenue of $7.83 million over the trailing twelve-month period, yet it simultaneously recorded a net income loss of $-64,923,000 and an EBITDA of $-74,035,000, highlighting a cost structure where expenses significantly exceed current income generation. The substantial gap between the $7.83 million in revenue and the $-64,923,000 in net income reveals that operating expenses, particularly in research and development, are driving a heavy financial burn rate typical of clinical-stage biotechs. Free cash flow stands at $-30,631,876, which indicates that the company is consuming cash reserves to fund its operations and does not yet possess the positive cash flow necessary to sustain itself without external financing. Three distinct margin metrics further illustrate this financial pressure: the gross margin is 0.0%, the operating margin is -1724.6%, and the profit margin is 0.0%. The zero gross margin suggests that cost of goods sold currently absorbs all revenue, while the deeply negative operating margin reflects high overhead costs relative to sales volume. The company holds $90.75 million in cash against a relatively low debt level of $2.12 million, resulting in a debt-to-equity ratio of 2.05. Although the debt-to-equity ratio is elevated, the dominance of cash assets suggests the balance sheet is funded primarily by equity and liquidity rather than traditional debt leverage. The current ratio is 3.36, which indicates a robust ability to meet short-term obligations with current assets, providing a buffer despite the negative earnings. Return on equity stands at -50.2% and return on assets is -24.3%, metrics that reveal management is currently destroying value on an accounting basis due to the heavy investment required to advance clinical trials before any product revenue is realized.
Waarderingsbeoordeling
The valuation metrics for Aclaris Therapeutics present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -5.39. The fact that the forward P/E is negative while the trailing P/E is unavailable implies that the market expects earnings to remain negative or that current earnings are insufficient to justify a traditional multiple, reflecting the speculative nature of the stock. The price-to-book ratio is 4.73, which indicates that the market values the company at a significant premium over its net asset value, a common scenario for biotech firms where intangible assets and pipeline potential outweigh book value. Alternative valuation measures such as the price-to-sales ratio of 62.51 and an EV/EBITDA of -5.38 further underscore that investors are pricing the stock based on revenue generation potential rather than earnings power. The stock has experienced significant volatility, trading between a 52-week high of $4.89 and a 52-week low of $1.08. Based on the provided data, the current price context relative to the 52-week range must be interpreted through the lens of this wide spread, which encompasses a potential trading range of over 350% from the low to the high. The beta value is 0.68, suggesting that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the overall index despite its high risk profile associated with the biotechnology sector.
Growth & Income
The company's revenue growth year-over-year is -85.9%, while earnings growth is listed as N/A, indicating that revenue has contracted significantly in the most recent period compared to the prior year. Since there are no reported positive earnings to grow, the comparison between earnings and revenue growth rates is not applicable in a traditional sense, as the firm is in a pre-profitability stage where revenue contraction may reflect specific commercialization challenges or strategic shifts. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available resources back into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current profitability and negative revenue growth, which is typical for clinical-stage companies that have not yet successfully commercialized their product candidates to generate sustainable cash flow.